EA202090587A1 - Способ получения сплит-вакцины с на гриппа - Google Patents

Способ получения сплит-вакцины с на гриппа

Info

Publication number
EA202090587A1
EA202090587A1 EA202090587A EA202090587A EA202090587A1 EA 202090587 A1 EA202090587 A1 EA 202090587A1 EA 202090587 A EA202090587 A EA 202090587A EA 202090587 A EA202090587 A EA 202090587A EA 202090587 A1 EA202090587 A1 EA 202090587A1
Authority
EA
Eurasian Patent Office
Prior art keywords
influenza
split vaccine
vaccine
split
stem region
Prior art date
Application number
EA202090587A
Other languages
English (en)
Inventor
Ёсимаса Такахаси
Ю Адати
Манабу Ато
Original Assignee
Джапэн Хелт Сайенсиз Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джапэн Хелт Сайенсиз Фаундейшн filed Critical Джапэн Хелт Сайенсиз Фаундейшн
Priority claimed from PCT/JP2018/032537 external-priority patent/WO2019045090A1/ja
Publication of EA202090587A1 publication Critical patent/EA202090587A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Предложен способ получения сплит-вакцины на основе HA гриппа, которая продуцирует антитело, которое связывается со стволовой областью HA гриппа, причем стволовая область HA менее вероятно подвергается антигенной изменчивости. Сплит-вакцину на основе HA гриппа подвергают кислотной обработке. Посредством кислотной обработки получают сплит-вакцину с HA, которая продуцирует антитело, которое связывается с LAH стволовой области HA. Эта сплит-вакцина против гриппа обладает превосходной способностью против заражения другими вирусами гриппа различной антигенности.
EA202090587A 2017-09-04 2018-09-03 Способ получения сплит-вакцины с на гриппа EA202090587A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017169230 2017-09-04
JP2018137952A JP7403733B2 (ja) 2017-09-04 2018-07-23 インフルエンザｈａスプリットワクチンの製造方法
PCT/JP2018/032537 WO2019045090A1 (ja) 2017-09-04 2018-09-03 インフルエンザｈａスプリットワクチンの製造方法

Publications (1)

Publication Number Publication Date
EA202090587A1 true EA202090587A1 (ru) 2020-08-24

Family

ID=65815411

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090587A EA202090587A1 (ru) 2017-09-04 2018-09-03 Способ получения сплит-вакцины с на гриппа

Country Status (10)

Country Link
US (1) US11732031B2 (ru)
EP (1) EP3679948A4 (ru)
JP (1) JP7403733B2 (ru)
KR (1) KR20200047629A (ru)
CN (1) CN111372605A (ru)
AU (1) AU2018325899B2 (ru)
CA (1) CA3074581A1 (ru)
EA (1) EA202090587A1 (ru)
PH (1) PH12020500414A1 (ru)
SG (1) SG11202001937TA (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
MX2021010685A (es) * 2019-03-04 2021-12-10 Sumitomo Pharma Co Ltd Método para producir vacuna fraccionada de hemaglutinina (ha) contra la influenza.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054481A2 (en) 2006-03-24 2008-05-08 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Improved inactivated influenza virus compositions
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
WO2010010467A2 (en) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2010047509A2 (ko) 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
CN101524538A (zh) * 2009-03-26 2009-09-09 成都康华生物制品有限公司 一种流感-大流行流感二价联合疫苗及其制备方法
WO2011111966A2 (en) 2010-03-08 2011-09-15 Celltrion, Inc. Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
ES2728433T3 (es) 2011-04-21 2019-10-24 Ology Bioservices Inc Procedimientos para aislar y cuantificar un antígeno de vacunas
CN104302317B (zh) * 2012-05-16 2016-07-06 Kj生物科学有限公司 新型和改进的流感疫苗
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
JP2017525766A (ja) 2014-08-18 2017-09-07 サノフィ パスツール インコーポレイテッド アルキル化インフルエンザワクチン
EP3240567A2 (en) 2014-12-31 2017-11-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Novel multivalent nanoparticle-based vaccines
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
KR20210034614A (ko) 2018-07-23 2021-03-30 국립감염증연구소장이 대표하는 일본국 인플루엔자 백신을 포함하는 조성물

Also Published As

Publication number Publication date
EP3679948A4 (en) 2021-04-28
AU2018325899A1 (en) 2020-04-09
CN111372605A (zh) 2020-07-03
EP3679948A1 (en) 2020-07-15
KR20200047629A (ko) 2020-05-07
US11732031B2 (en) 2023-08-22
CA3074581A1 (en) 2019-03-07
JP7403733B2 (ja) 2023-12-25
JP2019043937A (ja) 2019-03-22
US20190345231A1 (en) 2019-11-14
PH12020500414A1 (en) 2021-03-08
AU2018325899B2 (en) 2023-04-20
SG11202001937TA (en) 2020-04-29

Similar Documents

Publication Publication Date Title
CO2018004321A2 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
BR112016022113A2 (pt) anticorpos anti-hemaglutinina do vírus influenza b e métodos de uso
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
EA201691648A1 (ru) Способ получения противогрибковых соединений
EA201691649A1 (ru) Способ получения противогрибковых соединений
EA201791907A1 (ru) Бивалентная вакцина против вируса свиного гриппа
BR112017015880A2 (pt) anticorpos, usos e métodos
UY36394A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
MX2017016896A (es) Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos.
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
BR112018077210A8 (pt) Vírus de enterite de pato e usos do mesmo
EA201690857A1 (ru) Конъюгатные вакцины на основе сальмонеллы
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
EA202090587A1 (ru) Способ получения сплит-вакцины с на гриппа
BR112015032388A2 (pt) métodos e composições para as vacinas contra o vírus da dengue
MX363464B (es) Vacunas contra influenza h5.
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
JP2019043937A5 (ru)
WO2017053525A3 (en) Influenza vaccine and therapy
EA201990768A1 (ru) Оптимизированные синтетические консенсусные иммуногенные композиции, нацеленные на белок активации фибробластов
PE20190225A1 (es) Un metodo para reducir la contaminacion de huevo